MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:29Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Insulins]]
			[[Category:Long-acting insulins]]
			[[Category:Basal insulins]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #30

2026-05-23T03:34:49Z

parser-claude batch MedTemplate pre-fill, Top 300 #30

New page

{{MedTemplate
| generic = Insulin glargine
| brand = Lantus, Basaglar, Semglee, Toujeo (U-300)
| structure =
| classes = [[:Category:Insulins|Insulin]], [[:Category:Long-acting_insulins|Long-acting insulin analog]], [[:Category:Basal_insulins|Basal insulin]]
| uses = <vote slug="type1-diabetes-use">Type 1 diabetes mellitus</vote>, <vote slug="type2-diabetes-basal-use">Type 2 diabetes basal coverage</vote>
| starting_dose = ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose
| preparations = 100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens
| fda_max = Titrated to glucose; no fixed ceiling
| pill_id =
| routes = Subcutaneous (never IV; not for use in insulin pumps)
| onset = 1-2 hours
| duration = ~24 hours per dose (peakless profile by design)
| halflife = ~12 hours apparent (functional duration ~24 hours due to depot release kinetics)<ref name="lantus-label">FDA Prescribing Information, Lantus (insulin glargine), Sanofi-Aventis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021081s063lbl.pdf</ref>
| bioavailability = ~100% from subcutaneous depot (by definition of the route)
| pregnancy = Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="glargine-mech-claim">Insulin glargine is a recombinant human insulin analog (Gly-A21, two added Arg residues at B-chain C-terminus) that precipitates as microcrystals at physiologic pH after injection from its acidic formulation, producing slow continuous redissolution and a near-peakless 24-hour basal insulin profile.</vote> Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio; provides basal hepatic glucose suppression and peripheral glucose uptake without prandial peaks<ref name="lantus-label" />.
}}

== References ==
<references />

Insulin Glargine - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #30